Differentiation-coupled intron retention reveals a candidate NKG2D-TR-like isoform at the murine Klrk1 locus
NKG2D (encoded by KLRK1 in humans and Klrk1 in mice) is an activating receptor expressed by cytotoxic lymphocytes. In humans, NKG2D signaling is regulated post-transcriptionally: activated T cells retain intron 4 of KLRK1 to generate NKG2D-TR, a truncated dominant-negative isoform that limits receptor signaling. Whether mice, the principal preclinical model for NKG2D-directed therapies, possess…
NKG2D, a receptor found in cytotoxic lymphocytes, is activated in humans by post-transcriptional regulation. In mice, the connection between NKG2D regulation and intron retention remains unclear. In a study involving four RNA-seq datasets of 50 murine samples, researchers investigated the retained-intron isoform Klrk1-203. This transcript maintains its initial start codon, but its stop codon is within the final exon, potentially allowing it to bypass the genetic error-correction mechanism known as nonsense-mediated decay.
If expressed, Klrk1-203 would produce a truncated protein retaining essential cytoplasmic and transmembrane domains, but lacking most of the ligand-binding region. Unlike its human counterpart, the mouse protein contains a short C-terminal sequence from the retained intron. While Klrk1-203 was undetectable in unstimulated naive and early-effector T cells, it was induced in differentiated effector and memory populations, making up around one-fifth of total Klrk1 transcripts in one such sample.
Read-level analysis supported increased intron 4 retention during differentiation, but short-read sequencing could not conclusively separate Klrk1-203 from its co-retained counterpart Klrk1-204, necessitating model-based quantification. An independent coding-potential algorithm classified Klrk1-203 as non-coding, providing a contrasting perspective to the structural predictions.
The findings reveal Klrk1-203 as a potential NMD-resistant, differentiation-associated regulator of murine NKG2D and a possible counterpart of human NKG2D-TR that requires experimental validation.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.